<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633514</url>
  </required_header>
  <id_info>
    <org_study_id>1508151-6</org_study_id>
    <nct_id>NCT02633514</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma</brief_title>
  <official_title>A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether adjuvant radiochemotherapy after incomplete
      resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The previous trials have showed that radiotherapy was significantly associated with prolonged
      OS and chemotherapy is playing an increasing role in treatment of patients with thymoma or
      thymic carcinoma.However,whether patients with thymoma or thymic carcinoma could benefit from
      adjuvant radiochemotherapy after incomplete resection remains controversial. The purpose of
      this study is to investigate whether adjuvant radiochemotherapy after incomplete resection
      can improve survival for thymoma or thymic carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Thymoma and Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjuvant radiochemotherapy after incomplete resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>adjuvant radiotherapy after incomplete resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25mg/m2,iv gtt,d1-3</description>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>75mg/m2,iv gtt,d1-3</description>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>60Gy/30Fx</description>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_label>radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2;
        Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow,
        hepatic, and renal function;Patients receive incomplete resection within 3 months; Written
        informed consent.

        Exclusion Criteria:

        Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients
        who have malignancy history excluding carcinoma in situ of cervix in the previous five
        years; Active clinical pulmonary infection; Pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kailiang Wu, MD.PhD.</last_name>
    <phone>+86 64175590</phone>
    <phone_ext>86722</phone_ext>
    <email>wukailiang@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Yang</last_name>
    <email>842093447@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kailiang Wu</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kailiang Wu, M.D. Ph. D.</last_name>
      <phone>+86 64175590</phone>
      <phone_ext>86722</phone_ext>
      <email>wukailiang@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kailiang Wu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>thymoma</keyword>
  <keyword>thymic carcinoma</keyword>
  <keyword>adjuvant radiotherapy</keyword>
  <keyword>adjuvant radiochemotherapy</keyword>
  <keyword>incomplete resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

